Open Orphan PLC, a specialist pharmaceutical services company, and the world leader in the testing of vaccines and antivirals using human challenge studies, continues to make excellent progress towards maximising the capacity utilisation of its unique clinical facilities and services capabilities.
16 Nov 2020
Open Orphan: Sustaining commercial traction
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Open Orphan: Sustaining commercial traction
hVIVO plc (HVO:LON) | 28.8 0 0.0% | Mkt Cap: 195.6m
- Published:
16 Nov 2020 -
Author:
Emma Ulker -
Pages:
3
Open Orphan PLC, a specialist pharmaceutical services company, and the world leader in the testing of vaccines and antivirals using human challenge studies, continues to make excellent progress towards maximising the capacity utilisation of its unique clinical facilities and services capabilities.